05/06/21 4:04 PMNasdaq : KURA earningsKura Oncology Reports First Quarter 2021 Financial Results– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion cohorts enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients – – Data fromRHEA-AIvery positive
04/29/21 7:30 AMNasdaq : KURA conferencesearningsKura Oncology to Report First Quarter 2021 Financial ResultsKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after theRHEA-AIneutral
03/22/21 4:08 PMNasdaq : KURA clinical trialKura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS compared with median PFS of 3.6 months on last prior therapy (p=0.0012) – – Safety profile consistentRHEA-AIvery positive
02/24/21 7:20 AMNasdaq : KURA earningsKura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to include genetically enriched Phase 1RHEA-AIpositive
02/24/21 7:00 AMNasdaq : KURA Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell CarcinomaKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been grantedRHEA-AIpositive
02/18/21 7:30 AMNasdaq : KURA conferencesKura Oncology to Participate in Four Upcoming Investor ConferencesKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive officerRHEA-AIneutral
02/17/21 7:30 AMNasdaq : KURA conferencesearningsKura Oncology to Report Fourth Quarter and Full Year 2020 Financial ResultsKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2020 financialRHEA-AIneutral
01/07/21 7:30 AMNasdaq : KURA conferencesKura Oncology to Participate in H.C. Wainwright BioConnect 2021 ConferenceKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for theRHEA-AIneutral
01/06/21 7:30 AMNasdaq : KURA conferencesKura Oncology to Present at J.P. Morgan Healthcare ConferenceKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 39 th Annual J.P. Morgan HealthcareRHEA-AIneutral
12/11/20 4:05 PMNasdaq : KURA offeringKura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offeringRHEA-AIneutral